CASI Pharmaceuticals (CASI) announced the appointment of James Huang as an Independent Director to the CASI Board of Directors, effective as of October 1, 2025. As Founder and Managing Partner of Panacea Venture, and previously Managing Partner at Kleiner Perkins China and Vivo Ventures, he has guided numerous cross-border companies through critical stages of growth, financing, and global expansion. Panacea Venture is a current CASI Pharmaceuticals shareholder and, in connection with Mr. Huang’s appointment to the Board, plans to acquire up to approximately 1.5 million newly issued shares of CASI Pharmaceuticals common stock from CASI in a registered transaction.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CASI:
- CASI Pharmaceuticals Strengthens Board with Industry Veteran James Huang
- CASI announces SMC recommendation to escalate CID-103 dose to next cohort
- CASI Pharmaceuticals: Strategic Advancements and Leadership Strengthening Drive Buy Rating with $4.00 Price Target
- CASI Pharmaceuticals Strengthens Board with New Appointment
- Casi Pharmaceuticals appoints Barbara Krebs-Pohl to board of directors